Shenzhen Weiwu Guangming Biological Products

Shenzhen Weiwu Guangming Biological Products is a leading Chinese biopharmaceutical company focused on the research, development, and production of plasma-derived therapies. Established in 1984 and now operating as a subsidiary of China National Biotec Group (CNBG) under Sinopharm, the company is a key player in the national blood products industry. Its core portfolio features essential treatments such as human albumin, intravenous immunoglobulin (IVIG), and specialized immunoglobulins for rabies, tetanus, and hepatitis B. The company maintains advanced manufacturing facilities in Shenzhen that adhere to strict GMP standards to ensure the safety and efficacy of its biological products. Weiwu Guangming continues to support public health through the stable supply of life-saving blood-derived medicines across China.